# EDGAR Filing Document

**Accession Number:** 0001624326
**File Stem:** 0001493152-25-011458
**Filing Date:** 2025-7
**Character Count:** 26977
**Document Hash:** 3574205eb7d3617e6caa6cbd6690a690
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-011458.hdr.sgml**: 20250728

**ACCESSION NUMBER**: 0001493152-25-011458

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250728

**DATE AS OF CHANGE**: 20250728

**EFFECTIVENESS DATE**: 20250728

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PAVmed Inc.
- **CENTRAL INDEX KEY:** 0001624326
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471214177
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288997
- **FILM NUMBER:** 251155664

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (212) 949-4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAXmed Inc.
- **DATE OF NAME CHANGE:** 20141105

**As filed with the Securities and Exchange Commission on July 28, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**PAVMED INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **47-1214177** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

**360 Madison Avenue, 25th Floor**

**New York, NY 10017**

(Address of Principal Executive Offices) (Zip Code)

**PAVMED INC. SIXTH AMENDED AND RESTATED 2014 LONG-TERM INCENTIVE EQUITY PLAN**

(Full title of the plan)

**Dr. Lishan Aklog, Chairman and Chief Executive Officer**

**PAVmed Inc.**

**360 Madison Avenue, 25th Floor**

**New York, NY 10017**

(Name and address of agent for service)

**(917) 813-1828**

(Telephone number, including area code, of agent for service)

*with a copy to*:

**David Alan Miller, Esq.**

**Eric T. Schwartz, Esq.**

**Graubard Miller**

**The Chrysler Building**

**405 Lexington Avenue, 44<sup>th</sup> floor**

**New York, NY 10174**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**In accordance with the provisions of Rule 462 promulgated under the Securities Act of 1933, as amended, the Registration Statement will become effective upon filing with the Securities and Exchange Commission.**

**EXPLANATORY NOTE**

This registration statement is filed by PAVmed Inc. (the "Company") to register an additional 2,500,000 shares of the Company's common stock issuable pursuant to the Company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan (the "Plan"), which are newly reserved for issuance under the Plan as a result of an amendment to the Plan approved by the Company's board of directors and stockholders, and consists of only those items required by General Instruction E to Form S-8. The Company hereby incorporates by reference into this registration statement the contents of the prior registration statements on Form S-8 relating to the Plan, filed with the Securities and Exchange Commission (the "SEC") on May 20, 2021 (File No. 333-256343), August 4, 2021 (File No. 333-258459), and April 13, 2022 (File No. 333-264271), February 10, 2023 (File No. 333-269700), February 6, 2024 (File No. 333-276904) and January 31, 2025 (File No. 333-284637).

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1.** **Plan Information.\***

**Item 2.** **Registrant Information and Employee Plan Annual Information.\***

\* The information required by this Part I is omitted from this Registration Statement in accordance with rules and regulations under the Securities Act of 1933, as amended ("Securities Act"), and the Note to Part I of Form S-8. The documents containing the information specified in this Part I will be sent or given to employees, officers, directors or others as specified by Rule 428(b)(1) under the Securities Act. Such documents and the documents incorporated by reference herein pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

The following documents that we have previously filed with the SEC are incorporated by reference in this registration statement (excluding any reports or portions thereof that are furnished under Item 2.02 or Item 7.01 and any exhibits included with such items):

● The annual report on [Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000164117225000364/form10-k.htm) for the fiscal year ended December 31, 2024 (filed on March 24, 2025).

● The quarterly report on [Form 10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000164117225010433/form10-q.htm) for the period ended March 31, 2025 (filed on May 15, 2025).

● The current reports on Form 8-K dated [January 15, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000149315225002398/form8-k.htm) (filed on January 15, 2025), [January 17, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000149315225003053/form8-k.htm) (filed on January 21, 2025), [January 23, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000149315225003631/form8-k.htm) (filed on January 24, 2025), [February 14, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000149315225007094/form8-k.htm) (filed on February 18, 2025), [February 18, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000149315225007902/form8-k.htm) (filed on February 21, 2025), [March 5, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000149315225009698/form8-k.htm) (filed on March 10, 2025), [April 11, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000164117225003741/form8-k.htm) (filed on April 11, 2025), [April 17, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000164117225005279/form8-k.htm) (filed on April 17, 2025), [April 23, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000164117225006250/form8-k.htm) (filed on April 25, 2025), [June 18, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000164117225015612/form8-k.htm) (filed on June 18, 2025) and [June 23, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1624326/000164117225016227/form8-k.htm) (filed on June 24, 2025).

● The description of our common stock in the [Form 8-A](https://www.sec.gov/Archives/edgar/data/1624326/000157104916011221/t1600263_8-a12b.htm) filed on January 29, 2016, together with any amendment or report filed under the Exchange Act for the purpose of updating such description, including [Exhibit 4.1](https://www.sec.gov/Archives/edgar/data/1624326/000164117225000364/ex4-1.htm) to our annual report on Form 10-K for the fiscal year ended December 31, 2024.

All documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended ("Exchange Act"), prior to the filing of a post-effective amendment which indicates that all the securities offered have been sold or which deregisters all securities then remaining unsold (excluding any reports or portions thereof that are furnished under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items) will be deemed to be incorporated by reference in this registration statement and to be a part of this registration statement from the respective date of filing.

Any statement contained herein or in a document incorporated by reference herein will be modified or superseded for all purposes to the extent that a statement contained herein or in any other subsequently filed document which is incorporated by reference herein modifies or replaces the statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this registration statement.

Notwithstanding the foregoing, we are not incorporating any document or portion thereof or information deemed to have been furnished and not filed in accordance with SEC rule.

**Item 5.** **Interests of Named Experts and Counsel.**

Graubard Miller issued the opinion as to the legality of the shares of our common stock being registered pursuant to this registration statement.

**Item 8.** **Exhibits.**

See the Exhibit Index, which is incorporated herein by reference.

**Item 9.** **Undertakings.**

(a) The
 undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To
 file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To
 include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To
 reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
 post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
 forth in the registration statement;

(iii) To
 include any material information with respect to the plan of distribution not previously disclosed in the registration statement
 or any material change to such information in the registration statement.

*Provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That,
 for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
 to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
 be deemed to be the initial *bona fide* offering thereof.

(3) To
 remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
 termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(h) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing procedures, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on this 28<sup>th</sup> day of July, 2025.

---

| | |
|:---|:---|
| PAVMED INC. | PAVMED INC. |
| By: | */s/ Lishan Aklog, M.D.* |
|  | Lishan Aklog, M.D. |
|  | Chairman and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lishan Aklog, M.D. and Dennis M. McGrath, and each of them, with full power to act without the other, such person's true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign this registration statement, any and all amendments thereto (including post-effective amendments), and any amendments thereto and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | | |
|:---|:---|:---|:---|
| Signatures | Signatures | Title | Date |
| By: | */s/ Lishan Aklog, M.D.* | Chairman and Chief Executive Officer | July 28, 2025 |
|  | Lishan Aklog, M.D. | (Principal Executive Officer) |  |
| By: | */s/ Dennis M. McGrath* | President and Chief Financial Officer | July 28, 2025 |
|  | Dennis M. McGrath | (Principal Financial and Accounting Officer) |  |
| By: | */s/ Michael J. Glennon* | Vice Chairman and Director | July 28, 2025 |
|  | Michael J. Glennon |  |  |
| By: | */s/ Sundeep Agrawal, M.D.* | Director | July 28, 2025 |
|  | Sundeep Agrawal, M.D. |  |  |
| By: | */s/ Tim Baxter* | Director | July 28, 2025 |
|  | Tim Baxter |  |  |
| By: | */s/ Ronald M. Sparks* | Director | July 28, 2025 |
|  | Ronald M. Sparks |  |  |
| By: | */s/ Debra J. White* | Director | July 28, 2025 |
|  | Debra J. White |  |  |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [Certificate of Incorporation (incorporated by reference to the Registrant's Registration Statement on Form S-1, File No. 333-203569)](https://www.sec.gov/Archives/edgar/data/1624326/000157104915003049/t1500762_ex3-1.htm) |
| 3.2 | [Certificate of Amendment to Certificate of Incorporation, dated April 19, 2015 (incorporated by reference to the Registrant's Registration Statement on Form S-1, File No. 333-203569)](https://www.sec.gov/Archives/edgar/data/1624326/000157104915003049/t1500762_ex3-2.htm) |
| 3.3 | [Certificate of Amendment to Certificate of Incorporation, dated October 1, 2018 (incorporated by reference to the Registrant's Current Report on Form 8-K filed on October 2, 2018)](https://www.sec.gov/Archives/edgar/data/1624326/000149315218014004/ex3-1.htm) |
| 3.4 | [Certificate of Amendment to Certificate of Incorporation, dated June 26, 2019 (incorporated by reference to the Registrant's Current Report on Form 8-K filed on June 27, 2019)](https://www.sec.gov/Archives/edgar/data/1624326/000149315219009776/ex3-1.htm) |
| 3.5 | [Certificate of Amendment to Certificate of Incorporation, dated July 24, 2020 (incorporated by reference to the Registrant's Current Report on Form 8-K filed on July 27, 2020)](https://www.sec.gov/Archives/edgar/data/1624326/000149315220014017/ex3-1.htm) |
| 3.6 | [Certificate of Amendment to Certificate of Incorporation, dated June 21, 2022 (incorporated by reference to the Registrant's Current Report on Form 8-K filed on June 22, 2022)](https://www.sec.gov/Archives/edgar/data/1624326/000149315222017444/ex3-1.htm) |
| 3.7 | [Certificate of Amendment to Certificate of Incorporation, dated December 5, 2023 (incorporated by reference to the Registrant's Current Report on Form 8-K filed on December 5, 2023)](https://www.sec.gov/Archives/edgar/data/1624326/000149315223043666/ex3-1.htm) |
| 3.8 | [Certificate of Amendment to Certificate of Incorporation, dated January 15, 2025 (incorporated by reference to the Registrant's Current Report on Form 8-K filed on January 15, 2025)](https://www.sec.gov/Archives/edgar/data/1624326/000149315225002398/ex3-1.htm) |
| 3.9 | [Certificate of Elimination of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock (incorporated by reference to the Registrant's Current Report on Form 8-K/A filed on April 20, 2018)](https://www.sec.gov/Archives/edgar/data/1624326/000149315218005557/ex3-2.htm) |
| 3.10 | [Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (incorporated by reference to the Registrant's Current Report on Form 8-K/A filed on April 20, 2018)](https://www.sec.gov/Archives/edgar/data/1624326/000149315218005557/ex3-1.htm) |
| 3.11 | [Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to the Registrant's Current Report on Form 8-K filed on January 21, 2025)](https://www.sec.gov/Archives/edgar/data/1624326/000149315225003053/ex4-1.htm) |
| 3.12 | [Amended and Restated Bylaws (incorporated by reference to the Registrant's Current Report on Form 8-K filed on January 15, 2021)](https://www.sec.gov/Archives/edgar/data/1624326/000149315221001172/ex3-1.htm) |
| 4.1 | [Specimen PAVmed Inc. Common Stock Certificate (incorporated by reference to the Registrant's Registration Statement on Form S-1, File No. 333-203569)](https://www.sec.gov/Archives/edgar/data/1624326/000157104915008018/t1502053_ex4-2.htm) |
| 5.1 | [Opinion of Graubard Miller (filed herewith)](ex5-1.htm) |
| 10.1 | [PAVmed Inc. Sixth Amended and Restated Long-Term Incentive Equity Plan (incorporated by reference to Annex A of the Supplement to Proxy Statement filed on Schedule 14A filed on May 9, 2025)](https://www.sec.gov/Archives/edgar/data/1624326/000164117225009431/formdefa14a.htm) |
| 23.1 | [Consent of Marcum LLP (filed herewith)](ex23-1.htm) |
| 23.3 | [Consent of Graubard Miller (included in Exhibit 5.1)](ex5-1.htm) |
| 24.1 | [Power of Attorney (included on the signature page hereto)](#a_001) |
| 107 | [Calculation of Filing Fee Table (filed herewith)](ex107.htm) |

---

## Ex-5

**Exhibit 5.1**

![](ex5-1_001.jpg)

Facsimile Direct Dial

July 28, 2025

PAVmed Inc.

360 Madison Avenue, 25<sup>th</sup> Floor

New York, NY 10017

Ladies and Gentlemen:

Reference is made to the Registration Statement on Form S-8 (the "Registration Statement") filed by PAVmed Inc., a Delaware corporation ("*Company*"), under the Securities Act of 1933, as amended (the "*Act*"), with respect to an aggregate of 2,500,000 shares (the "*Shares*") of common stock, par value $.001 per share ("*Common Stock*"), newly reserved for issuance by the Company under the Company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan (the "*Plan*"), as a result of an amendment to the Plan that was duly approved by the Company's Board of Directors and stockholders.

We have examined such documents and considered such legal matters as we have deemed necessary and relevant as the basis for the opinion set forth below. With respect to such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies, and the authenticity of the originals of those latter documents. As to questions of fact material to this opinion, we have, to the extent deemed appropriate, relied upon certain representations of certain officers and employees of the Company.

In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as to, the authenticity and completeness of all documents submitted to us as originals, the genuineness of signatures on documents reviewed by us, the conformity to originals and the completeness of all documents submitted to us as copies, the legal capacity of all parties executing any documents (other than the Company), the lack of any undisclosed termination or modification or waiver of any document, the absence of any extrinsic agreements or documents that might change or affect the interpretation or terms of documents, and the due authorization, execution and delivery of all documents by each party thereto other than the Company. We have also assumed that any certificates or instruments representing the Shares, when issued, will be executed by the Company by officers of the Company duly authorized to do so. In rendering our opinion, we have also relied upon a good standing certificate regarding the Company issued by the Delaware Secretary of State and representations and certifications made to us by the Company, including, without limitation, representations that the Company has available a sufficient number of authorized shares of Common Stock that are not currently outstanding or reserved for issuance under other outstanding securities or plans of the Company, to enable the Company to issue and deliver all of the Shares as of the date of this letter. We have also assumed that in granting future awards under the Plan, the Board of Directors of the Company or the appropriate committee thereunder will exercise its discretion in establishing the terms of such awards in accordance with the terms of the applicable Plan and within the permissible limits of the law of the State of Delaware and the certificate of incorporation, as amended, and bylaws, as amended, of the Company.

Based upon and subject to the foregoing, it is our opinion that the Shares, when sold in accordance with the terms of the Plan and the individual instruments or agreements governing their issuance, will be legally issued, fully paid and nonassessable.

The opinion expressed herein is limited to the corporate laws of the State of Delaware, and we express no opinion as to the effect on matters covered by this letter of the laws of any other jurisdiction.

We hereby consent to the use of this opinion as an exhibit to the Registration Statement, to the use of our name as your counsel and to all references made to us in the Registration Statement. In giving this consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| */s/ Graubard Miller* |

---

## Ex-23

**Exhibit 23.1**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 24, 2025 with respect to the financial statements of PAVmed Inc. for the year ended December 31, 2024 included in the Annual Report on Form 10-K.

/s/ Marcum LLP

New York, NY

July 28, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Table**

**Form S-8**

(Form Type)

**PAVmed Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered<sup>(1)</sup>** | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee<sup>(2)</sup>** |
| Equity | Common Stock, $0.001 par value per share, reserved for issuance under 2014 Long-Term Incentive Equity Plan | Other<sup>(3)</sup> | 2500000 | $0.5840<sup>(3)</sup> | $1460000.00 | 0.0001531 | $223.53 |
| **Total Offering Amounts** | **Total Offering Amounts** |  |  |  | $1460000.00 |  | $223.53 |
| **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |  |  |
| **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** |  |  |  |  |  | $223.53 |

---

(1) Pursuant
 to Rule 416 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement
 also covers such additional securities that may be offered pursuant to the terms of the PAVmed Inc. Sixth Amended and Restated 2014
 Long-Term Incentive Equity Plan (the "Plan") as a result of one or more adjustments under the Plan to prevent dilution
 resulting from one or more stock splits, stock dividends or similar transactions.

(2) The
 Registrant does not have any fee offsets.

(3) Pursuant
 to Rule 457(h) and Rule 457(c) promulgated under the Securities Act, solely for the purpose of calculating the registration fee,
 the proposed maximum offering price per share for the shares reserved for future grants under the Plan is the average of the high
 and low prices of our common stock as reported on the Nasdaq Capital Market on July 23, 2025.